Malignant peripheral nerve sheath tumor: models, biology, and translation

被引:67
作者
Somatilaka, Bandarigoda N. [1 ]
Sadek, Ali [1 ]
McKay, Renee M. [1 ]
Le, Lu Q. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA
[3] Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX 75390 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX 75390 USA
[5] Univ Texas Southwestern Med Ctr Dallas, ODonnell Brain Inst, Dallas, TX 75390 USA
关键词
SOFT-TISSUE SARCOMA; FARNESYLTRANSFERASE INHIBITOR TIPIFARNIB; RECEPTOR TYROSINE KINASES; NEUROFIBROMATOSIS TYPE-I; CANCER STEM-CELL; SCHWANN-CELLS; MOUSE MODELS; PHASE-II; MOLECULAR CHARACTERIZATION; PLEXIFORM NEUROFIBROMAS;
D O I
10.1038/s41388-022-02290-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, invasive cancer that comprise around 10% of all soft tissue sarcomas and develop in about 8-13% of patients with Neurofibromatosis Type 1. They are associated with poor prognosis and are the leading cause of mortality in NF1 patients. MPNSTs can also develop sporadically or following exposure to radiation. There is currently no effective targeted therapy to treat MPNSTs and surgical removal remains the mainstay treatment. Unfortunately, surgery is not always possible due to the size and location of the tumor, thus, a better understanding of MPNST initiation and development is required to design novel therapeutics. Here, we provide an overview of MPNST biology and genetics, discuss findings regarding the developmental origin of MPNST, and summarize the various model systems employed to study MPNST. Finally, we discuss current management strategies for MPNST, as well as recent developments in translating basic research findings into potential therapies.
引用
收藏
页码:2405 / 2421
页数:17
相关论文
共 257 条
[81]  
Guo JM, 2020, AM J CANCER RES, V10, P856
[82]  
Guo JM, 2017, AM J CANCER RES, V7, P923
[83]   Malignant Peripheral Nerve Sheath Tumors [J].
Gupta, Gaurav ;
Mammis, Antonios ;
Maniker, Allen .
NEUROSURGERY CLINICS OF NORTH AMERICA, 2008, 19 (04) :533-+
[84]   Neurofibromatosis type 1 [J].
Gutmann, David H. ;
Ferner, Rosalie E. ;
Listernick, Robert H. ;
Korf, Bruce R. ;
Wolters, Pamela L. ;
Johnson, Kimberly J. .
NATURE REVIEWS DISEASE PRIMERS, 2017, 3
[85]   Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2 [J].
Hakozaki, Michiyuki ;
Hojo, Hiroshi ;
Sato, Michiko ;
Tajino, Takahiro ;
Yamada, Hitoshi ;
Kikuchi, Shinichi ;
Abe, Masafumi .
VIRCHOWS ARCHIV, 2009, 455 (06) :517-526
[86]   Protein Acetylation at the Interface of Genetics, Epigenetics and Environment in Cancer [J].
Harachi, Mio ;
Masui, Kenta ;
Cavenee, Webster K. ;
Mischel, Paul S. ;
Shibata, Noriyuki .
METABOLITES, 2021, 11 (04)
[87]  
Higham Christine S., 2017, Sarcoma, V2017, P8685638, DOI 10.1155/2017/8685638
[88]   Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation [J].
Hirbe, Angela C. ;
Dahiya, Sonika ;
Friedmann-Morvinski, Dinorah ;
Verma, Inder M. ;
Clapp, D. Wade ;
Gutmann, David H. .
ONCOTARGET, 2016, 7 (07) :7403-7414
[89]   BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors [J].
Hirbe, Angela C. ;
Pekmezci, Melike ;
Dahiya, Sonika ;
Apicelli, Anthony J. ;
Van Tine, Brian A. ;
Perry, Arie ;
Gutmann, David H. .
NEURO-ONCOLOGY, 2014, 16 (03) :466-467
[90]  
Hirokowa Y, 2005, CANCER BIOL THER, V4, P379